reports
Axway Software : Déclaration des transactions sur actions propres
PARIS--(BUSINESS WIRE)-- Regulatory News: Dans le cadre de l’autorisation consentie par l’Assemblée Générale mixte du 11 mai 2023 pour la mise en œuvre d’un programme de rachat d’actions, Axway Software SA (Paris:AXW) (LEI : 96950022O6SP7FQONJ77) déclare ci-après les achats d’actions propres (FR0011040500) réalisés du 8 au 12 avril 2024 : Jour de latransaction Volume total journalier(nombre de titres) Prix pondérémoyen d'acquisition(€/action) Montant des transactions(€) Code identifiantmarché 08/04/2024 626 25.49 15,957 XPAR 09/04/2024 481 25...
Moody's Ratings assigns definitive ratings to Wheels fleet lease ABS
Moody's Ratings has assigned definitive ratings to the series 2024-1 asset-backed notes (the series 2024-1 notes) issued by Wheels Fleet Lease Funding 1 LLC (the issuer). The underlying collateral backing the notes primarily consist of special units of beneficial interests (SUBIs) in a revolving poo...
Moody's Ratings announces completion of a periodic review of ratings o...
Moody's Ratings has completed a periodic review of the ratings of Nesco Holdings II, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 12 April 2024 in which Moody's Ratings reassessed the appropriateness of the ratings in the c...
Moody's Ratings announces completion of a periodic review of ratings o...
Moody's Ratings has completed a periodic review of the ratings of Belize and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 11 April 2024 in which Moody's Ratings reassessed the appropriateness of the ratings in the context of the rel...
Equity Bancshares, Inc. First Quarter Results Highlighted by Record Ne...
WICHITA, Kan.--(BUSINESS WIRE)-- Equity Bancshares, Inc. (NYSE: EQBK), (“Equity”, “the Company”, “we,” “us,” “our”), the Wichita-based holding company of Equity Bank, reported net income of $14.1 million or $0.90 earnings per diluted share for the quarter ended March 31, 2024. “Our Company entered the year positioned to take advantage of opportunities which we expect will drive our operating growth in the future,” said Brad S. Elliott, Chairman and CEO of Equity. “With our team’s proven, strategic skillset and cultivated relationships within our banking community, we were able to complete ou...
Moody's Ratings assigns provisional ratings to two classes of CLO refi...
Moody's Ratings has assigned provisional ratings to two classes of CLO refinancing notes (the "Refinancing Notes") to be issued by Octagon Investment Partners 28, Ltd. (the "Issuer"). Moody's Ratings' rating action is as follows: U.S.$6,750,000 Class X-RR Senior Secured Floating Rate Notes due 2...
GFG Issues Shares to IEP Pursuant to WWCC Gold Property Option Agreeme...
GFG Issues Shares to IEP Pursuant to WWCC Gold Property Option Agreement SASKATOON, Saskatchewan, April 16, 2024 (GLOBE NEWSWIRE) -- GFG Resources Inc. (TSX-V: GFG) (OTCQB:GFGSF) (“GFG” or the “Company”) announces that it has issued shares pursuant to the previously announced option agreement (the “Agreement”) with International Explorers and Prospectors Inc. (“IEP”) whereby GFG can acquire a 100% interest of the WWCC Property, located 40 kilometres east of Timmins, Ontario (see news release: “. Pursuant to the Agreement, GFG issued a total of 2,500,000 common shares of the Company to ...
Moody's Ratings says Resideo's acquisition of Snap One is credit posit...
Moody's Ratings commented that Resideo's announced acquisition of Snap One is credit positive, however, the ratings and outlook remain unchanged. On April 15, 2024, Resideo Funding Inc. (Ba2 stable) announced that it has entered into an agreement to acquire Snap One Holdings Corp. (B2 stable), a pro...
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinuma...
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab) SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva SELARSDI is expected to be marketed in the U.S. on or after February 21, 2025, following a settlement agreement with Johnson & Johnson, the manufacturer of StelaraSELARSDI was developed and is manufactured by Alvotech using murine cell (Sp2/0) and a continuous perfusion process, which are the same type of cells and proces...
Alvotech hlýtur markaðsleyfi í Bandaríkjunum fyrir Selarsdi (ustekinum...
Alvotech hlýtur markaðsleyfi í Bandaríkjunum fyrir Selarsdi (ustekinumab-aekn) líftæknilyfjahliðstæðu við Stelara Markaðsleyfið er fyrir notkun lyfsins til meðferðar bæði á fullorðnum og börnum Þetta er önnur líftæknilyfjahliðstæða Alvotech sem hlýtur markaðsleyfi í Bandaríkjunum Gert er ráð fyrir að Selarsdi komi á markað í Bandaríkjunum um eða eftir 21. febrúar 2025 í samræmi við samkomulag við framleiðanda frumlyfsins StelaraSelarsdi var þróað og er framleitt af Alvotech með sömu frumutegund og framleiðsluaðferð og notuð er við framleiðslu Stelara Alvotech (NASDAQ: ALVO) tilkynnti í da...
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab...
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab) SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva SELARSDI is expected to be marketed in the U.S. on or after February 21, 2025, following a settlement agreement with Johnson & Johnson, the manufacturer of StelaraSELARSDI was developed and is manufactured by Alvotech using murine cell (Sp2/0) and a continuous perfusion process, which are the same type of cells and process...
Moody's Ratings assigns MIG 1 to Fort Mill School District 4 (York Cou...
Moody's Ratings has assigned a MIG 1 rating to Fort Mill School District 4 (York County), SC's General Obligation Bonds, Series 2024A, which have a proposed par amount of roughly $5 million. Moody's Ratings maintains the district's Aa2 issuer rating, Aa2 general obligation unlimited tax (GOULT) rati...
River Valley Community Bancorp Announces 1st Quarter Results (Unaudite...
River Valley Community Bancorp Announces 1st Quarter Results (Unaudited) YUBA CITY, Calif., April 16, 2024 (GLOBE NEWSWIRE) -- River Valley Community Bancorp (OTC markets: RVCB) with its wholly owned subsidiary, River Valley Community Bank (collectively referred to as the “Bank”), today announced financial results for the quarter ended March 31, 2024. The full earnings release can be found on the Bank’s Investor Relations website at . The Bank remains highly rated with BauerFinancial, and Depositaccounts.com and serves its customer base through its offices located at: 1629 Colusa Avenue...
Panbela Announces Transfer to OTCQB Market
Panbela Announces Transfer to OTCQB Market MINNEAPOLIS, April 16, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that its common stock has been approved for quotation on the OTCQB market. Panbela’s common stock will be eligible for quotation on the OTCQB starting on April 17, 2024, under the symbol “PBLA.” OTCQB is a venture market operated by the OTC Markets Group Inc. To be eligible for quotation on the OTCQB, co...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.